As per the research report, the size of the North America HIV Diagnostics Market was valued at USD 850.20 million in 2022 and is estimated to be growing at a CAGR of 9.0%, to reach 1308.14 million by 2027 during the forecast period 2022 to 2027.
The human immunodeficiency virus (HIV) is a kind of retrovirus that causes (AIDS). HIV affects some immune cells, and it weakens the immune system bringing about a loss of capacity to fight against the organisms that cause diseases.
HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. Additionally, HIV can spread from infected mother to child during pregnancy. Some symptoms of HIV disease are weakness, slight fever, swollen glands, cerebral pains, and muscle hurts. The present situation is like various POC/rapid tests are under clinical advancement and examination in the item pipelines of significant market members and are relied upon to acquire regulatory approval in various local segments of the market. This normal increment in the quantity of item offerings to the worldwide market space is required to fuel the development of the HIV diagnostics industry over the forecast period.
Major factors driving the market are the technological advancement of disease diagnostic tests and the foreseen improvement and commercialization of novel, regulatory authorities approved POC and rapid CD4, p24 antigen, and EID tests; it is expected that all the major regional market segments will witness an expansion in market demand over the forecast period. As a result, there is a need to increase the introduction of easily accessible, efficient, robust diagnostics tests. Because of the financial resource-constrained settings in a massive share of the disease-affected regions, it is not yet feasible to perform the current complex screening, staging, and monitoring tests. This is either because of the absence of adequate testing labs or an absence of prepared clinical technicians capable of performing the tests. These limitations of laboratory-based testing catalyze the improvement of convenient and simple to execute point care and rapid tests.
The North America HIV Diagnostics Market is categorized based on Product, End-User, Type, and geography. The market is divided into Instruments, Consumables (Assays and Kits & Reagents, Other consumables), Software & Services. Based on Type, the market is segmented into HIV-2 & Group O Diagnostic Tests, Antibody Tests, Viral Identification Tests, Viral load testing, CD4 Testing, and Early Infant Diagnostics. Further, based on Antibody tests, the market is segmented into (HIV-1 Screening tests- Elisa/EIA, Home Access Dried blood spots. Rapid Tests), (HIV-1 Antibody Confirmatory Tests- Western Blot Test, Line immunoassays (Cnf), Indirect immunofluorescence Assays (IFA), Radio immunoprecipitation Assays (RIPA)). Based on HIV-2 & Group O Diagnostic Tests, the market is further categorized into Blood Antibody Tests, Line Immuno Assay (HIV-2), DBS Tests, and Viral Identification Tests; the market is divided into Qualitative PCR Tests, p24 Antigen tests, Viral Culture. The North American market is analyzed under various regions, namely the U.S and Canada. HIV Diagnostics Market was dominated by North America, with an overall market share of over 38% globally. North America was followed by Asia pacific.
Abbott Healthcare, Alere Inc., Abbvie Inc., Bristol-Myers Squibb, Gilead Sciences, Merck & Co. Inc, Janssen Therapeutics, BD Biosciences, VIIV Healthcare, Partec, Sysmex, Beckman Coulter, Apogee Flow Systems, Mylan inc., PointCare Technologies Inc., Zyomyx Inc., Roche Diagnostics, Siemens Healthcare, Qiagen, and bioMerieux are a few of the notable players operating in the North American HIV diagnostics market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org